NEOGENOMICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.14 USD | +2.09% |
|
+4.51% | -12.61% |
| Apr. 18 | NeoGenomics, Inc. Announces Senior Leadership Promotions | CI |
| Apr. 18 | NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,054 | 5,978 | 4,201 | 1,167 | 2,062 | 1,805 | - | - |
| Enterprise Value (EV) 1 | 3,054 | 5,853 | 4,496 | 1,515 | 2,332 | 2,092 | 2,077 | 2,031 |
| P/E ratio | 366 x | 1,346 x | -487 x | -7.97 x | -23.1 x | -25.1 x | -35.8 x | -45.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7.47 x | 13.5 x | 8.67 x | 2.29 x | 3.49 x | 2.76 x | 2.51 x | 2.29 x |
| EV / Revenue | 7.47 x | 13.2 x | 9.28 x | 2.97 x | 3.94 x | 3.19 x | 2.89 x | 2.57 x |
| EV / EBITDA | 53.4 x | 168 x | -1,080 x | -31.6 x | 669 x | 92.1 x | 45 x | 25.8 x |
| EV / FCF | 914,347,968 x | -211,772,255 x | -49,477,433 x | - | - | - | - | - |
| FCF Yield | 0% | -0% | -0% | - | - | - | - | - |
| Price to Book | 5.79 x | 8.69 x | 3.82 x | 1.18 x | 2.19 x | 2 x | 2.04 x | 1.99 x |
| Nbr of stocks (in thousands) | 104,408 | 111,030 | 123,122 | 126,303 | 127,466 | 127,666 | - | - |
| Reference price 2 | 29.25 | 53.84 | 34.12 | 9.240 | 16.18 | 14.14 | 14.14 | 14.14 |
| Announcement Date | 2/27/20 | 2/24/21 | 2/23/22 | 2/23/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 408.8 | 444.4 | 484.3 | 509.7 | 591.6 | 654.7 | 718.9 | 789.6 |
| EBITDA 1 | 57.22 | 34.84 | -4.161 | -48.01 | 3.486 | 22.7 | 46.18 | 78.73 |
| EBIT 1 | 13.01 | -13.99 | -118.8 | -157.6 | -107.7 | -87.07 | -67.39 | -58.47 |
| Operating Margin | 3.18% | -3.15% | -24.52% | -30.92% | -18.21% | -13.3% | -9.37% | -7.4% |
| Earnings before Tax (EBT) 1 | 3.645 | -14.06 | -15.08 | -159.3 | -97.1 | -79.79 | -59.96 | -50.73 |
| Net income 1 | 8.006 | 4.172 | -8.347 | -144.2 | -87.97 | -71.17 | -51.6 | -41.4 |
| Net margin | 1.96% | 0.94% | -1.72% | -28.3% | -14.87% | -10.87% | -7.18% | -5.24% |
| EPS 2 | 0.0800 | 0.0400 | -0.0700 | -1.160 | -0.7000 | -0.5629 | -0.3950 | -0.3100 |
| Free Cash Flow | 3.34 | -27.64 | -90.86 | - | - | - | - | - |
| FCF margin | 0.82% | -6.22% | -18.76% | - | - | - | - | - |
| FCF Conversion (EBITDA) | 5.84% | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | 41.72% | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/24/21 | 2/23/22 | 2/23/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 121.3 | 125.7 | 117.2 | 125.1 | 128.8 | 138.7 | 137.2 | 146.9 | 152 | 155.6 | 149.7 | 162.7 | 167.8 | 174.6 | 166.2 |
| EBITDA 1 | -3.113 | -9.785 | -19.01 | -16.27 | -11.56 | -1.168 | -7.116 | -2.051 | 3.305 | 9.348 | -0.5692 | 4.264 | 6.442 | 12.39 | 5.196 |
| EBIT 1 | -39.71 | -41.57 | -52.03 | -39.7 | -39.51 | -26.38 | -35.07 | -29.89 | -24.2 | -18.57 | -27.71 | -22.99 | -21.17 | -15.38 | -22.76 |
| Operating Margin | -32.73% | -33.06% | -44.4% | -31.74% | -30.68% | -19.02% | -25.56% | -20.35% | -15.92% | -11.94% | -18.51% | -14.14% | -12.61% | -8.81% | -13.69% |
| Earnings before Tax (EBT) 1 | -23.17 | -44.2 | -53.16 | -41.03 | -39.62 | -25.52 | -33.72 | -26.64 | -21.45 | -15.29 | -25.21 | -21.24 | -19.83 | -14.39 | -20.06 |
| Net income 1 | -20.35 | -41.76 | -49.41 | -35.3 | -36.85 | -22.69 | -30.8 | -24.33 | -18.52 | -14.33 | -23.12 | -18.86 | -17.49 | -12.48 | -17.56 |
| Net margin | -16.77% | -33.21% | -42.17% | -28.23% | -28.62% | -16.36% | -22.44% | -16.56% | -12.19% | -9.21% | -15.44% | -11.6% | -10.42% | -7.15% | -10.57% |
| EPS 2 | -0.1700 | -0.3400 | -0.4000 | -0.2800 | -0.3000 | -0.1800 | -0.2500 | -0.1900 | -0.1500 | -0.1100 | -0.1814 | -0.1471 | -0.1371 | -0.0986 | -0.1360 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/23/22 | 4/27/22 | 8/9/22 | 11/8/22 | 2/23/23 | 5/8/23 | 8/8/23 | 11/6/23 | 2/20/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 295 | 348 | 269 | 286 | 272 | 225 |
| Net Cash position 1 | - | 125 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -70.86 x | -7.242 x | 77.22 x | 12.62 x | 5.883 x | 2.862 x |
| Free Cash Flow | 3.34 | -27.6 | -90.9 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 1.93% | 0.69% | -3.63% | -6.63% | -1.53% | 0.25% | 1.67% | - |
| ROA (Net income/ Total Assets) | 1.32% | - | - | - | - | - | - | - |
| Assets 1 | 607.3 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 5.050 | 6.190 | 8.930 | 7.860 | 7.390 | 7.070 | 6.930 | 7.110 |
| Cash Flow per Share 2 | 0.2300 | 0.0100 | -0.2200 | -0.5300 | -0.0200 | 0.4400 | 0.7000 | - |
| Capex 1 | 20 | 29.1 | 64.1 | 30.9 | 28.8 | 29.2 | - | - |
| Capex / Sales | 4.9% | 6.55% | 13.24% | 6.06% | 4.86% | 4.46% | - | - |
| Announcement Date | 2/27/20 | 2/24/21 | 2/23/22 | 2/23/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
14.14
USD
Average target price
21.1
USD
Spread / Average Target
+49.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.61% | 1.81B | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -15.34% | 1.03B |
- Stock Market
- Equities
- NEO Stock
- Financials NeoGenomics, Inc.
